Navigation Links
Elcelyx Therapeutics' NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet™, the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. 

The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced fasting plasma glucose to a similar extent as generic metformin but at plasma exposure levels previously shown to be as much as 65% lower than comparable doses of generic metformin.

The double-blind, dose-finding trial evaluated NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There were also two comparator arms with Glucophage XR dosed once-daily at 1,000 and 2,000 milligrams. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. Twelve-week results are expected in late October.

The results at four weeks provide confirmation that the primary site of metformin activity is the lower bowel and not the circulation.  The reduced systemic absorption of NewMet indicates that it may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.

About Elcelyx Therapeutics, Inc.

Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity. Elcelyx is based in San Diego, CA. For more information, vi
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
2. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
3. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
4. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
5. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
6. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
7. PTC Therapeutics to Present at Upcoming Investor Conferences
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
10. Echo Therapeutics Announces Management Changes
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... , Nov. 24, 2014 Juno Therapeutics ... Therapy Designation to the company,s JCAR015 chimeric antigen ... treatment of relapsed or refractory B-cell acute lymphoblastic ... Memorial Sloan Kettering Cancer Center, where Phase 1 ... "The FDA,s action is important news for patients ...
(Date:11/24/2014)... , Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced today that Sergio ... at the LD MICRO "MAIN Event" Micro-Cap Growth Conference ... held at the Luxe Sunset Bel Air Hotel, which ... Los Angeles, California . The presentation ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today ... the majority that Restanza(TM) (cethromycin) demonstrated safety for ... pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). ... efficacy in the treatment of CAP (3 positive, 11 ...
... June 2 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today announced ... Biomedical Advanced Research and Development Authority (BARDA) in ... advanced research and development of medical countermeasures for ...
Cached Medicine Technology:Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 2Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 2PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 4PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 5
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 For its December issue ... AIS Report on Blue Cross and Blue Shield Plans* ... the varied strategies the two Blues plans are implementing ... treatments for sleep apnea, ranging from brick-and-mortar retail stores ... linked to increased rates of a variety of serious ...
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... With a redesign of the practice ... has enhanced the user experience and functionality of ... an online destination for orthopedic and sports medicine knowledge ... new and improved version of the website. The ... ever for current and prospective patients to find answers ...
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5
... Novel HIV Drug to be Studied in Cell ... A $6 million, five-year federal grant to The ... to investigate a novel approach in treating HIV infection ... therapies for psychological and neurological effects in AIDS. ...
... to concerns that the human papillomavirus vaccine might promote ... found that the majority of respondents did not believe ... infections. The study, conducted by University of Illinois ... and in the November issue of the Journal ...
... utter words , THURSDAY, Oct. 15 (HealthDay News) -- ... how the human brain computes language. , "Two central ... study: one, the way in which higher cognitive processes ... two, the nature of what is perhaps the best-known ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... ... the life science, engineering and entertainment industries, announced today they have signed an intellectual ... incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer of ...
... , NEW YORK, Oct. 15 The Nielsen Company ... CLIO Awards , one of the world,s most recognized international advertising ... "The Dr. Oz Show" and featured health expert ... Honorary CLIO Healthcare Award live at the first-ever CLIO Healthcare ...
Cached Medicine News:Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Brain Yields Up Clues to Language 2Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 2Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 3